ACADIA Pharmaceuticals Inc
ACAD
NASDAQ
Biotechnology
$28.24
USD
-0.14 (-0.49%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $4.89B
Volume 1.1M
Revenue
$1.14B
TTM
+11.8%
YoY
Gross Margin
91%
TTM
-0.9%
YoY
Net Income
$380.48M
TTM
+71.3%
YoY
Operating Cash Flow
$160.32M
TTM
-14.7%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 264.6 | 278.6 | 284.0 | 268.1 | 308.0 |
YoY Growth | +9.3% | +11.3% | +9.4% | +9.7% | +16.4% |
Cost of Revenue | 20.7 | 21.6 | 26.2 | 24.8 | 28.3 |
Gross Profit | 243.8 | 257.0 | 257.8 | 243.3 | 279.6 |
Selling, General & Administrative | 133.5 | 133.4 | 155.6 | 171.0 | 160.3 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 211.5 | 221.2 | 240.4 | 247.9 | 241.8 |
Operating Income | 32.4 | 35.8 | 17.4 | -4.6 | 37.8 |
EBITDA | 29.9 | 38.7 | 20.3 | -1.6 | 35.5 |
Other Income / Expense | 0.6 | 0.6 | 0.6 | 0.5 | 0.6 |
Total Other Income / Expense | 7.8 | 8.8 | 8.9 | 8.6 | 8.6 |
Income Before Income Taxes | 40.2 | 44.6 | 26.3 | 4.0 | 46.5 |
Income Taxes | 13.5 | -27.2 | -247.2 | 0.3 | 15.0 |
Net Income | 26.7 | 71.8 | 273.6 | 3.6 | 31.5 |
Consolidated Net Income / Loss | 26.7 | 71.8 | 273.6 | 3.6 | 31.5 |
Net Income Attributable to Common Shareholders | 26.7 | 71.8 | 273.6 | 3.6 | 31.5 |
Basic EPS | $0.16 | $0.43 | $1.61 | $0.02 | $0.18 |
Diluted EPS | $0.16 | $0.42 | $1.58 | $0.02 | $0.18 |
Basic Shares Outstanding | 167.8M | 168.8M | 170.0M | 170.5M | 171.6M |
Diluted Shares Outstanding | 168.7M | 170.7M | 172.7M | 172.7M | 172.9M |